ATLANTA — If you want to avoid shingles — a condition that comes with a painful rash — there is a vaccine available. But studies have shown that protection generated by the vaccine declines quickly.
A new vaccine, however, is being considered for approval, and if and when the Food and Drug Administration gives it the green light, its may hit the market with a highly desirably preferential rating from an influential panel of vaccine experts.
About the Author Reprints
““A preferential recommendation will make a difference here,” Bresnitz told the committee. “Let the market determine what happens here.”
Translation: Let marketing, not the data, decide.